dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
dQ&A launches a new tracking study of Italians with type 1 and type 2 diabetes, capturing real-world insights on care, technology use, and daily challenges.
Our study reveals that perceptions of hypoglycemia profoundly shape life with diabetes, exposing its broad mental, emotional, and physical toll.
A 3,000-person dQ&A survey shows 9% of those with T1D and 17% of those with T2D on insulin reported that they have self-rationed insulin because of cost.
Our research found that diabetes keeps many awake at night due to symptoms, complications, and comorbidities of diabetes.
Our quarterly U.S. survey shows diabetes sharply reduces productivity and daily-life capacity—evidence that employers must offer stronger support.
Our quarterly U.S. diabetes survey found one-third of respondents had mild or severe depression, underscoring the need for more support and better treatments.
Erik Shoger presented real-world patient insights at the FDA advisory meeting on sotagliflozin, highlighting the need for education and training if approved.
